Associated Papers
Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.
Zhang N et al.
Biomolecules, 2025
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.
Shen J et al.
Medcomm, 2023
Regulation of p53 and Cancer Signaling by Heat Shock Protein 40/J-Domain Protein Family Members.
Kaida A et al.
International Journal of Molecular Sciences, 2021
Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S et al.
Cancers, 2018
Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
De Smet F et al.
The Journal of Pathology, 2017
Alterations in Mitochondrial and Endoplasmic Reticulum Signaling by p53 Mutants.
Giorgi C et al.
Frontiers in Oncology, 2016
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA et al.
Blood Cancer Journal, 2015
TP53 mutants in the tower of babel of cancer progression.
Bisio A et al.
Human Mutation, 2014
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.
Martinez-Rivera M et al.
Biochemical Pharmacology, 2012
Tissue microarray cytometry reveals positive impact of homeodomain interacting protein kinase 2 in colon cancer survival irrespective of p53 function.
Soubeyran I et al.
The American Journal of Pathology, 2011
Select a paper to view details